Los puntos clave no están disponibles para este artículo en este momento.
Despite predicted and previously reported resistance, osimertinib may have durable efficacy against rare EGFR L747P mutations. Persistent attempts to acquire material for tumor genomic analysis may yield results critically important to clinical management.
Gerber et al. (Tue,) studied this question.